MEB Seminar: Professor Brian M. D'Onofrio
Title: ADHD Medication and Substance Use Problems: Pharmaco-epidemiology studies in Sweden and the US
Dr. Brian D'Onofrio comes from the Department of Psychological and Brain Sciences, Indiana University, Bloomington. His research is rooted in the field of developmental psychopathology, explores the causes and treatments of child and adolescent psychopathology through three main approaches: quasi-experimental designs, longitudinal analyses, and intervention studies.
Arranged by: The Doctoral Programme in Epidemiology and SINGS Research School
Attention Deficit/Hyperactivity Disorder (ADHD) is a common and relatively stable developmental disorder that is associated with significant disability. Drug treatment of ADHD is now widely used in the United States and in Europe. Randomized controlled trials (RCTs) suggest that ADHD medication has beneficial short-term effects on symptoms of ADHD and some co-occurring disorders. RCTs of ADHD medication have serious limitations, however, including the inability to generalize to individuals with serious comorbid problems, study rare and serious outcomes, and adequately examine long-term outcomes. Thus, the increasing use of ADHD medications is being heavily debated because of the uncertainty regarding both short-term and long-term effects, particularly concerns about misuse and overuse. In this seminar I will discuss how our research teams is trying to more precisely identify the specific risks and benefits of ADHD medication for substance use problems, particularly with samples and designs that can explore rare outcomes with long follow-up time and treatments periods. I will present findings from analyses of datasets from Sweden (using national registers) and the United States (using health insurance claims) that used within-individual comparisons and advanced statistical techniques to account for stable and time-varying confounding.Contact person: Ralf Kuja-Halkola